Paper42979192PubMed
Research advances in Janus kinase inhibitors for immune checkpoint inhibitors-related myocarditis.
Leng J and 2 others. Front Immunol, 2026.
Cite this record
ConductScience Library. Research advances in Janus kinase inhibitors for immune checkpoint inhibitors-related myocarditis. Papers, record 42979192. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42979192
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Research advances in Janus kinase inhibitors for immune checkpoint inhibitors-related myocarditis.
- Journal
- Front Immunol
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-11-05
Source PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Janus Kinase Inhibitors | Major topic |
| Myocarditis | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Humans | |
| Animals | |
| Signal Transduction | |
| Janus Kinases |
Source PubMed
References82
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39210332 | Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study. | J Transl Med | 2024 | https://conductscience.org/library/papers/39210332 | PubMed |
| 2 | 38701735 | Baricitinib protects ICIs-related myocarditis by targeting JAK1/STAT3 to regulate Macrophage polarization. | Cytokine | 2024 | https://conductscience.org/library/papers/38701735 | PubMed |
| 3 | 41826213 | Risk of first and second primary keratinocyte cancers in relation to treatment of rheumatoid arthritis with JAKi, TNFi, and non-TNFi bDMARDs-a Swedish nationwide study. | Ann Rheum Dis | 2026 | https://conductscience.org/library/papers/41826213 | PubMed |
| 4 | 35383117 | Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. | J Immunother Cancer | 2022 | https://conductscience.org/library/papers/35383117 | PubMed |
| 5 | 38346306 | Immune-Related Adverse Events of Immune Checkpoint Inhibitors. | Ann Intern Med | 2024 | https://conductscience.org/library/papers/38346306 | PubMed |
| 6 | 38486105 | Prmt7 regulates the JAK/STAT/Socs3 signaling pathway in postmenopausal cardiomyopathy. | Exp Mol Med | 2024 | https://conductscience.org/library/papers/38486105 | PubMed |
| 7 | 34986285 | Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. | N Engl J Med | 2022 | https://conductscience.org/library/papers/34986285 | PubMed |
| 8 | 29567210 | Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. | J Am Coll Cardiol | 2018 | https://conductscience.org/library/papers/29567210 | PubMed |
| 9 | 37187275 | Regulation of the JAK/STAT signaling pathway: The promising targets for cardiovascular disease. | Biochem Pharmacol | 2023 | https://conductscience.org/library/papers/37187275 | PubMed |
| 10 | 37020552 | Case report: Myocarditis in congenital STAT1 gain-of function. | Front Immunol | 2023 | https://conductscience.org/library/papers/37020552 | PubMed |
| 11 | 41314979 | JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/41314979 | PubMed |
| 12 | 41422438 | Serious Infection Risk With TNF Inhibitors vs. JAK Inhibitors in Rheumatoid Arthritis: A Nationwide Claims-Based Cohort Study. | Clin Pharmacol Ther | 2026 | https://conductscience.org/library/papers/41422438 | PubMed |
| 13 | 41419971 | Safety of JAK inhibitors versus other biologic therapies following anti-TNF failure in patients with rheumatoid arthritis. | Arthritis Res Ther | 2025 | https://conductscience.org/library/papers/41419971 | PubMed |
| 14 | 31960755 | Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. | J Am Heart Assoc | 2020 | https://conductscience.org/library/papers/31960755 | PubMed |
| 15 | 42034889 | Superior drug retention of selective JAK1 inhibitors compared to pan-JAK inhibitors in rheumatoid arthritis: A meta-analysis of real-world evidence. | Semin Arthritis Rheum | 2026 | https://conductscience.org/library/papers/42034889 | PubMed |
| 16 | 39991658 | Identification of Necroptosis and Immune Infiltration in Heart Failure Through Bioinformatics Analysis. | J Inflamm Res | 2025 | https://conductscience.org/library/papers/39991658 | PubMed |
| 17 | 40592184 | Small molecular inhibitors targeting Janus kinases (JAKs) for the treatment of psoriasis. | Eur J Med Chem | 2025 | https://conductscience.org/library/papers/40592184 | PubMed |
| 18 | 9287210 | STATs and gene regulation. | Science | 1997 | https://conductscience.org/library/papers/9287210 | PubMed |
| 19 | 33645548 | Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. | J Clin Invest | 2021 | https://conductscience.org/library/papers/33645548 | PubMed |
| 20 | 40794245 | Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review. | Dermatol Ther (Heidelb) | 2025 | https://conductscience.org/library/papers/40794245 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42979192
GET https://conductscience.org/api/papers/v1/42979192/references?page=2